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Platelets are rapidly activated by several agonists. When phorbol 12-my&ate 13-acetate (PMA) was added 
to washed platelet suspensions 10 s prior to either thrombin or ADP, it caused a dose-dependent inhibition 
of shape change correlated with decreased myosin association with the cytoskeleton and with inhibition of 
the calcium transient measured in fura-Zloaded platelets. PMA added SlO s after agonists did not reverse 
shape change or the association of myosin with the cytoskeleton, but markedly increased the rate at which 
the calcium signal returned to the baseline. The analogue, 4a-phorbol didecanoate did not cause these ef- 
fects. Our results suggest hat one effect of C-kinase activation is to provide negative feedback in sequential 
responses. 
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1. INTRODUCTION 
Platelet stimulation by agonists is followed in 
seconds by shape change [ 11. A rise in free calcium 
is thought to be the triggering mechanism [2]. The 
free Ca2+ is most probably mobilized by myo- 
inositol-1,4,5triphosphate (IP3), released from 
phosphatidylinositol 4,5-bisphosphate (PIP2) by 
phospholipase C [3]. Another product of this reac- 
tion, 1 ,Zdiacylglycerol (DG), activates Ca’+,phos- 
pholipid-dependent protein kinase C (C-kinase), 
which synergizes with Ca2+ to potentiate secretion 
not only in platelets but also in many cells [4,5]. 
Phorbol ester, which can substitute for DG to 
activate C-kinase [a], also activates platelets, but 
slowly and differently from agonists [7-91. Yet 
Abbreviations: PMA. phorbol l%-myristate 13-acetate; 
DG, 1 ,Zdiacylglycerol; 4cu-PDD, 4cu-phorbol dideca- 
noate; C-kinase, Ca2+,phospholipid-dependent protein 
kinase; IP3, myo-inositol 1,4,5_triphosphate; MLCK, 
myosin light chain kinase; PRP, platelet-rich plasma 
some recent studies have demonstrated that pre- 
treatment with phorbol esters for 2-3 min inhibits 
Ca2’ mobilization in several cell types [lo-151. In 
a sequential set of rapid responses, such activation 
of C-kinase is too slow to be significant. To see if 
activation of C-kinase could occur rapidly enough 
to modify agonist actions, we looked at early ef- 
fects of phorbol esters. 
2. EXPERIMENTAL 
Shape change of washed platelets was monitored 
by absorbance (A) scans as described in the legend 
to fig. 1. As shown (left panel), 0.025 U/ml throm- 
bin induced shape change in 15 s as indicated by a 
rapid rise in A and loss of the oscillatory response 
characteristic of stirred discoid platelets 
(monitored by phase microscopy). PMA (Sigma, 
St. Louis) added 10 s before thrombin inhibited 
these responses: a strong effect was seen at 0.5 nM 
PMA, while 100 nM PMA prevented the rise in A 
completely. The scanning electron micrographs of 
fig.2 show that platelets pretreated with PMA were 
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Fig.1. The effect of PMA on shape change induced by thrombin or ADP. Blood was drawn from healthy volunteers 
as approved by the Human Subjects Committee. Platelets were washed twice as described [27] and suspended in a 
Tyrode-Hepes buffer (TH buffer) containing 140 mM NaCl, 2.5 mM KCl, 0.5 mM NaHsPOd, 10 mM NaHCOs, 
0.1 mM MgC12, 10 mM Hepes, 0.35% bovine serum albumin and 0.1% glucose. During the washing 0.1 mg/ml apyrase 
(Sigma A-6132, 1.2 ADP U/mg) was added. Absorbance (A) of stirred platelets was monitored in a Gilford 
spectrophotometer at 37°C according to Born [28] using maximum sensitivity. EGTA was added at 1 mM 30 s before 
each incubation. The traces are typical of several similar experiments using platelets from different donors. 
inhibited from extending filopodia and undergoing 
shape change in response to thrombin. PMA at 
lower concentrations similarly inhibited ADP- 
induced shape change (fig. 1, right). PMA added 
5 s after thrombin or ADP did not restore A or the 
oscillatory signal (right center). PMA alone caused 
a slow loss of oscillatory record after about 2 min 
without increase in A (bottom right); irregular 
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Fig.2. Scanning electron micrographs of platelets treated 
with ADP or with PMA prior to ADP. Washed platelets 
were treated with solvent (a) or with 20 nM PMA for 
10 s (b) prior to 1OpM ADP for 15 s (both) and then 
fixed with 2% formaldehyde, 0.2% glutaraldehyde in 
Tyrode buffer for 30 min then allowed to settle on 
polylysine-L-coated coverslips for 30 min. The 
coverslips were rinsed with buffer and fixed overnight at 
4°C in 2% glutaraldehyde in Tyrode buffer. The 
samples were dehydrated in an ethanol series, critical 
point dried and coated with gold platinum (approx. 
150 A). The pretreatment with PMA prevented the 
emergence of fine filopodia and the change in shape to 
irregular spheres. 
spheres were observed as previously reported using 
electron microscopy [7]. 
Shape change is believed to be caused at least in 
part by the interaction of actin with myosin ac- 
tivated by the phosphorylation of the myosin 
regulatory light chain by Ca*+,calmodulin- 
dependent light chain kinase (MLCK) [ 11, which is 
correlated with increased association of myosin 
with the cytoskeleton [16,17]. PMA treatments 
altered the composition of cytoskeletons by SDS 
gel electrophoresis (fig.3). After addition of 
thrombin or ADP, myosin and actin increased in 
Fig.3. SDS gel electrophoresis of platelet cytoskeletons 
after stimulation with thrombin, ADP, or PMA alone or 
in conjunction with agonists. Cytoskeletons were 
prepared by adding an equal volume of 2070 Triton 
X-100, 20 mM imidazole-HCl, 20 mM EGTA, pH 7.0, 
to washed platelet suspensions, left on ice for 5-15 min 
before centrifugation at 1400 x g for 10 min, and 
washed with a 1: 1 mixture of TH buffer and Triton lysis 
buffer. The precipitates were dissolved in Laemmli 
buffer and electrophoresed on a 7.5% SDS-containing 
gel by the method of Laemmli [29]. Experimental 
conditions: 0.5 ml platelets (1 x PRP concentration) in 
Tyrode-Hepes buffer containing 1 mM EGTA were 
either treated with 50 nM PMA alone (lanes 2,3) or with 
agonists (lanes 5,6,9,10). Lanes: 1, control; 2, PMA 
30 s; 3, PMA 2 min; 4, 0.025 U/ml thrombin 10 s; 5, 
PMA followed 10 s later by thrombin 10 s before lysis; 
6,0.025 U/ml thrombin followed 10 s later by PMA for 
50 s before lysis; 7, 0.025 U/ml thrombin for 60 s; 8, 
ADP 10 s; 9, PMA followed 10 s later by ADP 10 s; 10, 
ADP followed 10 s later by PMA 50 s; 11, ADP 60 s. 
The three polypeptides which appear above actin in 
cytoskeletons after thrombin (lanes 4-7) are due to 
fibrin [30]. 
the cytoskeletons (lanes 4,7,8,11) as reported for 
thrombin but not previously observed for ADP 
[16]. Pretreatment with 50 nM PMA for 10 s in- 
hibited the association of myosin with 
cytoskeletons induced by 0.025 U/ml thrombin 
(cf. lanes 4,5) or by 10 pM ADP (lanes g,9) but had 
little or no effect when added 5 s after the agonists 
(cf. lanes 6,7 and 10,ll). Cytoskeletons of platelets 
treated with PMA (50 nM) for 2 min but not for 
30 s contained increased amounts of actin and a 
small amount of myosin (lanes 2,3). Increased 
myosin and actin in cytoskeletons parallels the oc- 
currence of shape change as manifested by the loss 
in oscillatory signals in fig.1, but maximum shape 
change occurs after ADP with less cytoskeletal 
myosin than is observed after thrombin. 
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Fig.4. Effects of PMA on calcium transients induced by thrombin or ADP. Platelets suspended in Mill’s buffer [27] 
were incubated with fura- (Molecular Probes, Junction City, OR) at 2/rg/ml for 30 min at 37°C in the dark. After 
being sedimented and resuspended, the loaded platelets were rested for 15-30 min at 37’C. Ca2’ measurements were 
performed as in [l&19] in the presence of 1 mM EGTA (A,B,E,G,H) or 1 mM CaCl2 (C,D,F). 
We measured Cai” using fura- [ 181 as described 
[19]. Fig.4 shows the rapid rise in Ca?’ after 
thrombin or ADP. The signal after thrombin 
lasted about 120 s, while that after ADP only 
about 20 s. We observed a remarkably rapid dose- 
dependent inhibition of the calcium signal by PMA 
added 10 s before agonists. The correlation of 
PMA inhibition on the Ca2+ signals and the shape 
change induced by 0.025 U/ml thrombin was as 
follows: PMA at 1, 10, and 50 nM inhibited shape 
change (10 s) by 50, 70, and 90%, and suppressed 
Ca2+ signals (as measured by the area under the 
curves) by 50, 80, and 85% in the absence of exter- 
nal Ca’+. The transient, smaller Ca’+ signal pro- 
duced by 10pM ADP in the absence of external 
Ca2+ was completely inhibited by pretreatment 
with 20 nM PMA for 10 s, correlating with the 
greater sensitivity of ADP-induced shape change 
to PMA. We also observed inhibition of 80% of 
the Ca2+ signal induced by 0.5 U/ml thrombin 
with 50 nM PMA even with external Ca2+ (fig.4C). 
Remarkably, PMA added after thrombin in- 
creased the rate of return of the calcium signal to 
the baseline and even caused an overshoot 
(fig.4B,D). This result may be due to the use of the 
fura- method which has higher sensitivity than the 
quin-2 method, particularly in measuring decreases 
in Ca2+ [ 191. 4rr-PDD, which cannot activate C- 
kinase, did not produce inhibition (fig.4C,D). 
3. DISCUSSION 
PMA acts more rapidly than previously ob- 
served in platelet studies: e.g. lo-20 ng/ml PMA 
was used for 3 min to produce a 90% inhibition of 
the thrombin-induced Ca2+ signal [lo], or 160 nM 
PMA was used for 2 min [l 1,121. Fig.4E shows 
that the inhibition of calcium signal by 20 nM 
PMA is essentially complete after less than 60 s. In 
previous studies, platelets would have already 
undergone atypical, PMA-induced shape change 
before the addition of agonists. These effects of 
PMA appear to be due to C-kinase activation 
because they were mimicked by 1-oleoyl-Zacetyl- 
glycerol, an analogue of DG, but not by rku-PDD, 
which cannot activate C-kinase, and they occurred 
as rapidly as the phosphorylation of 47 kDa pro- 
tein, which reached 70% of maximum by 10 s [6]. 
Does this mean that the normal decline in the 
calcium signal is due to some C-kinase activation? 
Or, do mechanisms uch as those dependent on 
cyclic AMP work to remove the calcium signal 
soon after it occurs? It has recently been reported 
that phorbol ester can prevent the agonist- 
dependent inhibition of platelet adenylate cyclase 
which takes place via an inhibitory Ni protein [20]. 
On the other hand, C-kinase phosphorylates 
phospholamban to activate the calcium pump of 
heart sarcoplasmic reticulum [21]. Recently, we 
found that a membrane fraction from PMA- 
treated platelets takes up labelled calcium at about 
3-times the rate of control membranes (un- 
published). 
Pretreatment with PMA for more than 1 min 
has been reported to inhibit thrombin-induced 
Ca2+ transients by suppressing IP3 production 
[10,12]. In addition, PMA phosphorylates an in- 
hibitory site (C-kinase site) on the myosin P light 
chain, reducing the contractility of the actomyosin 
[25], an effect which could increase inhibition of 
myosin-dependent events, such as shape change, if 
it occurred rapidly. 
Much evidence supports the idea of a synergism 
between Ca2+ and C-kinase in the mechanism of 
secretion (review [5]). However, the present data 
show that PMA, presumably by activating C- 
kinase can act to inhibit early Ca2+-mediated 
events. We suggest that C-kinase may act as a tem- 
poral regulator for a series of sequential responses, 
turning off early events and stimulating those that 
occur later in a sequence. 
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